Innovate for health @CSEM 17.09.2014

1. 1IBM Technology Day 2013, Keynote B. Dubuis11.6.2013
Click to edit Master title style
© BD, ROI
© 2013 IBM Corporation
Biotech, Medtech and
Bioconvergence
Dr. Benoit Dubuis,
President BioAlps & Inartis-Network,
Executive Director Campus Biotech
17.09.2014

2. HEALTH CARE
“Medical revolution and new technologies”
The challenges
Towards bioconvergence
Our contribution
Anticipate the Future

3. HEALTH CARE
“Medical revolution and new technologies”
The challenges
Towards bioconvergence
Our contribution
Anticipate the Future

4. Crossing Visions
19.09.2014 | 4
MAJOR CHALLENGES
IN HEALTHCARE
Therapeutic challenges
Demographics
Cost
Access
Variation in clinical practice
Inefficient use of information
Fragmented care versus integrated care
Duplication, defensive medicine & waste
Protracted adoption of innovation

5. Crossing Visions
19.09.2014 | 5
CAUSES
OF DEATH

6. Crossing Visions
19.09.2014 | 6
DEMOGRAPHICS:
WE LIVE
LONGER
LifeExpectancyatBirth
Benchmark:
Life expectancy in imperial Rome was ~ 30 years
1900 1950 2010 2050
CH: 80.5
CH: 84.7
Age 60 – 2 Billion
Age 80 – 380 Million
Age 100 – 2 Million
Benchmark:
Life expectancy in imperial Rome was ~ 30 years
Age 60 – 2 Billion
Age 80 – 380 Million
Age 100 – 2 Million

7. Crossing Visions
19.09.2014 | 7
HEALTH CARE
COSTS

8. Crossing Visions
19.09.2014 | 8
THE BURDEN OF
CHRONIC DISEASES
Healthcare
spending for people
with chronic
conditions
Nearly half of us will have
chronic conditions
by 2030:
Diabetes
Neurodegenerative Disease
Obesity
Hypertension
Arthritis
Atherosclerosis
Stroke
Cancer
Degenerative Joint disease
Degenerative Spine Disease
Obstructive Lung Disease
Healthcare
spending for people
without chronic
conditions
Chronic conditions
account for 83%
of health care
spending

9. NEW NEEDS IN
NEURO-ENGINEERING

10. Crossing Visions
19.09.2014 | 10
TOWARD
HEALTHIER
LIFE
Past model
Present model
Compressed morbidity model
Healthy life
Healthy life
Disease
Disability
Disease
Disability
Healthy life Life years gainedDisease
Disability

11. 11IBM Technology Day 2013, Keynote B. Dubuis11.6.2013
Click to edit Master title style
MEDTECH
“Medical revolution and new technologies”
The challenges
Towards Bioconvergence
Our contribution
Anticipate the Future

12. Crossing Visions
19.09.2014 | 12
CHANGING FOCUS
ON HEALTH CARE
Technology convergence
Pharmacogenomics
3P medicine
Translational medicine
Wireless Health

13. TOWARDS AN
INTEGRATED HEALTH SYSTEM
Rx
2009

14. Crossing Visions
19.09.2014 | 14
INNOVATION BY
BIOCONVERGENCE

15. Crossing Visions
19.09.2014 | 15
EXPLORE
INTERFACES

16. Crossing Visions
19.09.2014 | 16
NEXT GENERATION
PLATFORM TECHNOLOGIES
NEW
PRODUCTS
NEW
SOLUTIONS

17. Crossing Visions
19.09.2014 | 18
THE STRENGTH
OF THE
NETWORK
CLINICAL
CENTERS
ACADEMIC
CENTERS
CORE
FACILITIES
INDUSTRY
START-UPS





18. 191/30/2014 www.republic-of-innovation.ch Dr. B. Dubuis
Interdisciplinarity (science driven)

19. What is a Stent
A small, mesh-like device made of metal
Acts as a support or scaffold, in keeping the vessel open
Stent helps to improve blood flow to the heart muscle and reduce
the pain of angina
80% of patients who have balloon angioplasty will have a stent
placed as well.

20. History
Percutaneous transluminal coronary angioplasty (PTCA) by
Gruntzig in 1977
Puel and Sigwart, in 1986, deployed the first coronary stent to act
as a scaffold
In 2001, drug-eluting stents (DES) were introduced as a strategy
to minimize restenosis

21. Types
Bare metal stents:
Traditional method
May have an increased rate of
re-narrowing due to growth of scar
tissue in the stent, a condition called
Restenosis.
Drug-eluting
stents:
Combat Restenosis
Coated with medications that are slowly released
to block the body's ability to form scar tissue
around the stent. The medication is delivered
directly to the site of the artery blockage.

22. 23IBM Technology Day 2013, Keynote B. Dubuis11.6.2013
Click to edit Master title style
MEDTECH
“Medical revolution and new technologies”
The challenges
Towards an integrated health system
Our contribution
Innovation: The New Currency of
Competition

23. Crossing Visions
19.09.2014 | 24
MICRO /
NANO
CLUSTER
BIOCLUSTER
A UNIQUE HUB
FOR MEDTECH & BIOTECH

24. WORLD-CLASS
ACADEMIC
INSTITUTIONS
Generate Knowledge
Create Opportunities

25. 261/30/2014 www.republic-of-innovation.ch Dr. B. Dubuis
'evolutionary developmental biology'
Electronic health record'
Access to tools and knowledge

26. 271/30/2014 www.republic-of-innovation.ch Dr. B. Dubuis
The shift to patient-empowering, information-
leveraging technologies
“PI” (patient-empowering and information-leveraging) technologies

27. 291/30/2014 www.republic-of-innovation.ch Dr. B. Dubuis
Molecular and personalized medicine
Proficient use of Information (e.health)
Genomic & physiology
Access, Cost and Quality of care

28. 301/30/2014 www.republic-of-innovation.ch Dr. B. Dubuis
INNOVATION
The New Currency of Competition

29. 311/30/2014 www.republic-of-innovation.ch Dr. B. Dubuis
EXPLORE
NEWAVENUES

30. 321/30/2014 www.republic-of-innovation.ch Dr. B. Dubuis
WHERE
HISTORYWRITES
Towards
CampusBiotech

31. 331/30/2014 www.republic-of-innovation.ch Dr. B. Dubuis
WHERE
HISTORYWRITES
ENSURINGTHAT
HISTORYGOESON

33. Crossing Visions
19.09.2014 | 35
NEW
PATHS

34. 361/30/2014 www.republic-of-innovation.ch Dr. B. Dubuis

35. 371/30/2014 www.republic-of-innovation.ch Dr. B. Dubuis
ACCELERATE
TECHTRANSFER

36. 381/30/2014 www.republic-of-innovation.ch Dr. B. Dubuis
Support
Technology Transfer

37. 391/30/2014 www.republic-of-innovation.ch Dr. B. Dubuis
INARTIS NETWORK, NTN
R&D Projects
(CTI)
Workshops
Events
Networking

38. 40IBM Technology Day 2013, Keynote B. Dubuis11.6.2013
Click to edit Master title style
MEDTECH
“Medical revolution and new technologies”
The challenges
Towards an integrated health system
Our contribution
Anticipate the Future

39. Crossing Visions
19.09.2014 | 41
750 compantie
25’000 employee

40. Crossing Visions
19.09.2014 | 42
Support the growth
Anticipate the Future
Vitesse moyenne de croissance annuelle 95-00, 00-06
Source: BAK, Basel Economics

41. 431/30/2014 www.republic-of-innovation.ch Dr. B. Dubuis
A Successfull biocluster
Established
access to Capital
Experienced
Business and
Law Firms
Carve-Outs/
Spinouts
Experienced
Entrepreneur Innovation
Initiatives
World-Class
Research
Institutions
Experienced
Technical People
World-Class
Business Schools
PhDs
MBAs
Early-Stage
Company
Late-Stage
Emerging/Public
Public
Industry Leader
IP
Create Value
around IP
Create Value
C://DUBUIS, 2009

42. © 2014 INARTIS
© 2013 IBM Corporation
Find the slides on:
www.republic-of-innovation.ch
Dr. Benoit Dubuis
bd@republic-of-innovation.ch